The main drug used for decades to combat malaria in sub-Saharan Africa is facing a growing threat. Researchers have identified mutations that could be responsible for rising drug resistance, specifically a gene called px1.

These mutations, dubbed PIN (for its three amino acid and two deletion characteristics), are spreading rapidly through the parasite population. By 2024, over 80% of northern Uganda’s malaria parasites carried these mutations.

The findings highlight the urgency of developing new treatments to combat drug-resistant malaria. 'Malaria still is a major killer,' warns Jeffrey Bailey from Brown University. 'Drug resistance undermines our ability to control its spread.'

Further research showed that parasites with the PIN mutation were less sensitive to lumefantrine, an essential part of the treatment artemether-lumefantrine. However, no clear differences were observed for another drug, artemisinin.

The mutation first appeared in 2008 and has since spread across Uganda. Despite its rapid rise, its global impact remains unclear due to limited historical data. Continued surveillance is crucial to predicting when drugs will become ineffective.